LeanDreams: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.leandreamsweightloss.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “The following claims concerning compounded semaglutide and tirzepatide appear on your website:”

2. 2

   “• “Compounded Semaglutide has the same active ingredient as Ozempic and Wegovy.””

3. 3

   “• “With compounded Tirzepatide, you get the same active ingredient found in Mounjaro and Zepbound.””

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

leandreamsweightloss.com returned a live site on 2026-08-09 titled "Weight Loss Solutions | Lean Dreams ~ Transform Your Life!", positioned around a "12-Week Executive Transformation", fronted by a named bariatric surgeon (Dr. Jay Jorge, MD) and offering an assessment, a strategy-session booking and a published phone number. The phrase "same active ingredient" did not appear in the homepage as fetched — that is an observation about one page on one day, not a claim about the whole site.

Most of the sentences FDA quoted across this wave are labels: a product title with a brand in brackets after it. These two are explanations. "Compounded Semaglutide has the same active ingredient as Ozempic and Wegovy" is a sentence written to be believed rather than skimmed, and "With compounded Tirzepatide, you get the same active ingredient found in Mounjaro and Zepbound" addresses the reader directly, in the second person, about what they will receive. That is a harder thing to shrug off than a bracket, and it is worth naming why FDA still called it misleading: the statement about the molecule may be literally arguable, but what it delivers is a conclusion about the PRODUCT, and the product has not been through the review the brand names stand for. An approval covers a specific manufacturer, a specific formulation, a specific strength and a specific set of controls — none of which travels with an ingredient. The page today has moved on to a physician-fronted twelve-week programme, and the cited phrase was not on its homepage when checked. That is progress you can see, not a ruling: FDA has not closed this letter out, and it made no finding about how the products were made or what was in them.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence LeanDreams failed to respond.